Novo Nordisk shares fall 16% after weak obesity drug trial results
The selloff follows disappointing data from a next-generation obesity candidate, deepening pressure on the Danish company's incretin franchise.
TR
By Tom Reyes · Markets Editor
Feb 23 03:00 ETSource: Financial Times
The wire
- 01Novo Nordisk shares dropped 16% after the company reported trial results for a new obesity drug that fell short of investor expectations, the Financial Times reports.
- 02Novo's pipeline beyond semaglutide matters to prescribers and telehealth operators planning around future incretin supply, pricing and competition with Eli Lilly.
- 03Full trial data and the company's next regulatory steps will determine whether the candidate advances; the share move reflects market reaction, not a regulatory decision.
From the source
Read at ft.comNovo Nordisk shares drop 16% after poor trial results for new obesity drug
